Expertise in
3
conditions

Zan H. Shen

No. 600, Yishan Road, 
Shanghai, CN 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
3
conditions
No. 600, Yishan Road, 
Shanghai, CN 

Overview

Zan Shen practices in Shanghai, China. Shen is highly rated in 3 conditions, according to our data. Their top areas of expertise are Osteosarcoma, Bone Tumor, Adult Soft Tissue Sarcoma, Vertebroplasty, and Colonoscopy.

Their clinical research consists of co-authoring 149 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

No. 600, Yishan Road, Shanghai, 200233, China
Other Locations
Xizhan Branch, Lanzhou, China
600 Yishan Rd, Shanghai, 200233, China
Shanghai Jiao Tong University Affiliated Sixth People's Hospital 600 Yishan Rd, Shanghai, 200233, China
No. 600, Yishan Road, Xuhui, 200233, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
Enrollment Status: Recruiting
Publish Date: February 25, 2026
Intervention Type: Drug
Study Drugs: Anlotinib, Decarbazine
Study Phase: Phase 3

149 Total Publications

MTG2 as a Causal and Druggable Target in Uveal Melanoma via Mitochondrial DNA Dynamics: Evidence From Functional Validation and DMSA Identification.
MTG2 as a Causal and Druggable Target in Uveal Melanoma via Mitochondrial DNA Dynamics: Evidence From Functional Validation and DMSA Identification.
Journal: Investigative ophthalmology & visual science
Published: February 12, 2026

Frequently Asked Questions about Zan H. Shen

Is Zan H. Shen a top-rated expert for Osteosarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Zan H. Shen is classified as an Distinguished expert for Osteosarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Zan H. Shen participate in research or clinical trials?

Yes. Zan H. Shen has published 149 articles and abstracts on conditions like Osteosarcoma. You can view a list of Zan H. Shen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Shen's expertise for a condition
ConditionClose
    View All 17 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile